Comparing the current results to its competitors, Roivant Sciences Ltd reported Revenue decrease in the 4 quarter 2026 year on year by -66.71 %, despite the revenue increase by the most of its competitors of 6.62 %, recorded in the same quarter.
In a recent development, Roivant and Priovant announced that their Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus failed to meet its primary endpoint. Despite this setback, Roivant Sciences Ltd, the parent company of Roivant and Priovant, reported a substantial revenue increase in the third quarter of 2023. However, this growth fell below the average revenue growth of its competitors. This article delves into the implications of the disappointing study results for Roivant and analyzes its revenue growth performance amidst fierce competition in the pharmaceutical industry. Disappointing Clinical Trial Outcome: Roivant and Priovant s highly a...
Alpine Immune Sciences Inc is a biotechnology company focused on developing immunotherapies to treat cancer and autoimmune diseases. Their business model involves identifying unique protein targets and using their proprietary technology platform to engineer and develop novel therapeutic antibodies that modulate the immune system. They aim to partner with pharmaceutical companies for the clinical development and commercialization of their product candidates.
Moonlake Immunotherapeutics's business model revolves around the development and commercialization of innovative immunotherapies for the treatment of diseases.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Sources:
Roivant Sciences Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Roivant Sciences Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
